BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04927247 (Inclacumab in Sickle Cell Disease and Recurrent Vaso-occlusive…): BVCT ex-ante prediction vs. reported outcome

On 15 Jan 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 15 Aug 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT04927247
Acronym
THRIVE-132
Drug Name
Inclacumab
Drug MoA
anti-P-selectin mAb inhibitor
Drug Modality
monoclonal antibody (mAb)
Drug Class
Best-In-Class
Therapeutic Area
Hemic and Lymphatic Diseases
Indication
Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Human Patients
243
Sponsor
Pfizer
Phase
Phase 3

Prediction of , index 1418

Prospective Prediction
Prediction Index
1418
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
578 days in advance
Readout Data Interpretation
inclacumab failed to achieve meet the primary efficacy endpoint compared with placebo
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Phase
Phase 3
Status
Terminated
Enrollment
72
Lead sponsor
Pfizer
Conditions
Sickle Cell Disease; Vaso-occlusive Crisis; Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
DRUG: Inclacumab; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2021-12-09
Primary completion
2023-11-24
Completion
2023-11-24
Results first posted
2024-12-11
Primary outcomes
  • Percentage of Participants With at Least 1 VOC That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication Within 90 Days of Randomization (Within 90 days of randomization (randomization happened on Day 1 [Day 1 to Day 91]))

NCT04927247 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials